Clinical Trial Detail

NCT ID NCT00720785
Title Natural Killer Cells and Bortezomib to Treat Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

chronic lymphocytic leukemia

Ewing sarcoma

adenocarcinoma

pancreatic adenocarcinoma

chronic myeloid leukemia

colorectal cancer

lung non-small cell carcinoma

lung small cell carcinoma

renal cell carcinoma

multiple myeloma

prostate adenocarcinoma

melanoma

carcinoma

CLL/SLL

Therapies

Bortezomib

Age Groups: senior adult

No variant requirements are available.